General Information
Drug ID
DR00459
Drug Name
Fluoxetine
Synonyms
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine; (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine;(+/-)-Fluoxetine; (+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine; (+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]; (+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine; 3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; Animex-On; Dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; Eufor; Floxetine; Fluoxetin; Fluoxetina; Fluoxetina [INN-Spanish]; Fluoxetina [Spanish]; Fluoxetine (Prozac); Fluoxetine (TN); Fluoxetine (USAN/INN); Fluoxetine Hcl; Fluoxetine [USAN:INN:BAN]; Fluoxetinum; Fluoxetinum [INN-Latin]; Fluval; Fontex; Lilly-110140; Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine; Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine; N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine; Portal; Prozac (TN); Prozac Weekly; Pulvules; Reconcile; Reneuron
Drug Type
Small molecular drug
Indication Depression [ICD11: 6A8Z] Approved [1]
Therapeutic Class
Antidepressants
Structure
3D MOL 2D MOL
Formula
C17H18F3NO
Canonical SMILES
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F
InChI
InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3
InChIKey
RTHCYVBBDHJXIQ-UHFFFAOYSA-N
CAS Number
CAS 54910-89-3
Pharmaceutical Properties Molecular Weight 309.33 Topological Polar Surface Area 21.3
Heavy Atom Count 22 Rotatable Bond Count 6
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 5
XLogP
4
PubChem CID
3386
PubChem SID
11341994 , 11362177 , 11364573 , 11367135 , 11369697 , 11372694 , 11374305 , 11377859 , 11466539 , 11467659 , 11485551 , 11486118 , 11487579 , 11489474 , 11491463 , 11492428 , 11495493 , 143844 , 14874184 , 26751973 , 29222521 , 3249391 , 3719648 , 46507902 , 47365860 , 47515964 , 47515965 , 47589652 , 47662955 , 47960412 , 48111113 , 48259912 , 48259913 , 48416026 , 49698967 , 49833486 , 49880992 , 50104648 , 50319599 , 5367839 , 53787367 , 56312230 , 56312679 , 56312978 , 56313632 , 57321770 , 7847392 , 7979254 , 8152157 , 841244
ChEBI ID
ChEBI:5118
TTD Drug ID
D0TR5X
DT(s) Transporting This Drug P-GP Transporter Info P-glycoprotein 1 Substrate [2]
References
1 Fluoxetine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Fluoxetine and reversal of multidrug resistance. Cancer Lett. 2006 Jun 18;237(2):180-7.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.